Background {#Sec1}
==========

Obesity and diabetes mellitus Type 2 (T2DM) are rapidly growing public health problems in the Saudi population \[[@CR1], [@CR2]\]. A high risk of T2DM and cardiovascular complication is also associated with increased obesity \[[@CR2], [@CR3]\]. Several epidemiological and clinical studies have shown that human obesity is a multifactorial disorder, with both genetic predisposition and environmental factors contributing to its etiology \[[@CR4], [@CR5]\]. Extensive studies have linked different genetic loci to obesity, and strong linkage has between reported between beta (β) adrenoceptor polymorphisms (ADRB) and obesity or weight gain \[[@CR6]--[@CR10]\]. There are three subtypes of ARDB: β-1, β-2, and β-3, and these are involved in development, behavior, smooth muscle tone, heart function, and energy metabolism \[[@CR11]\]. The three β -subtypes (β-1, β-2, and β-3) coexist in both white adipose tissue (WAT) and brown adipose tissue (BAT). In WAT, ADRB signaling is thought to stimulate lipolysis in response to fasting, whereas in BAT, it mediates heat production in response to cold exposure or overfeeding via activation of the uncoupling protein-1(UCP1) \[[@CR12]--[@CR14]\]. Catecholamines are regulators of lipolysis, and act via β1-, β2-, β3- (stimulatory), and α2- (inhibitory) adrenoceptor subtypes in adipose tissue. Most of the sympathetic nervous system-mediated energy expenditure in skeletal muscles takes place via the coupling of catecholamines with β2-adrenoceptors \[[@CR15], [@CR16]\] and plays important roles in energy expenditure and control of body weight \[[@CR9]--[@CR17]\]. Recently, it has been shown that *ARDBs* are polymorphic with single nucleotide polymorphism (SNPs) exerting functional consequences affecting receptor activity and regulation, and hence may contribute to the pathophysiology of obesity and related disorders \[[@CR7]--[@CR9]\]. Several studies have shown an association between *ADRB* polymorphism and BMI, T2DM, hypertension \[HT\] and dyslipidaemias, while other studies have failed to show such an association \[[@CR18]--[@CR53]\].

In our previous report, we have shown a link between obesity-related disorders in Saudi population and Gln27Glu polymorphism in *ARDB2* gene \[[@CR9]\]. In the present study, we have investigated the relationship between polymorphism in *ARDB1* (rs1801253) and *ARDB3* (rs4994) genes and obesity and related disorders in the Saudi population.

Methods {#Sec2}
=======

Study group {#Sec3}
-----------

The study was approved by the local ethics committee at the Umm Al Qura University, Makkah Al Mukaramah, Saudi Arabia (IRB No. 235). It included randomly chosen 329 unrelated Saudi subjects \[men = 109 (33.1%) and women = 220 (66.9%)\], from a nationwide population, with ages ranging from 18 to 36 years. Informed written consent was obtained from all study subjects before their participation.

Anthropometric and biochemical measurements {#Sec4}
-------------------------------------------

Anthropometric measurements included the recording of height, weight, waist and hip circumference by standard methods. Body mass index (BMI; kg/m^2^) and waist-to-hip ratio (WHR) were calculated \[[@CR54]\]. For biochemical studies, 20 ml of blood was drawn by venipuncture from an antecubital vein without compression, following an overnight fast, from each subject under study. 10 ml blood was placed in ethylenediaminetetraacetic acid (EDTA) coated tubes, 2 ml in tubes containing fluoride and the rest in plain tubes. All samples were immediately centrifuged at room temperature to collect the plasma/serum. Plasma glucose was determined in duplicate by a glucose-oxidase method adapted to an autoanalyzer (Hitachi 704, Boehringer Mannheim, Germany). Enzymatic methods using commercial kits (Boehringer Mannheim) were used to estimate total serum cholesterol, triglycerides, low-density lipoprotein \[LDL\] and high-density lipoprotein \[HDL\]. Plasma insulin and leptin concentrations were estimated by radioimmunoassay (RIA) using Human Insulin Specific RIA kit and Human Leptin RIA Kit, respectively (Linco Research, St Louis, MO).

Genotyping of *ADRB1* polymorphism (rs1801253**)** {#Sec5}
--------------------------------------------------

The genomic DNAs of all the subjects were extracted from peripheral blood leukocytes using Gentra Systems Kit (Minneapolis, MN, cat \# D5500). The DNA fragment containing codon 389 of the *ARDB1* gene was amplified by polymerase chain reaction (PCR) using a sense primer (5'-CTCTTCGTCTTCTTCAACTGGCT-3′) and an antisense primer (5'-CAACAAGGAACATCAGCAAGC-3′). The PCR conditions consisted of an initial denaturation step at 95 °C for 15 min, followed by 34 cycles of denaturation at 95 °C for 1 min, annealing at 60 °C for 1 min, and extension at 72 °C for 1 min, with a final extension of 10 min at 72 °C. With these primers, a PCR product was verified on 2% agarose gel electrophoresis. Nucleotide sequencing was carried out by the ABI Big Dye Terminator protocol using ABI 3100 Avant Genetic Analyzer.

Genotyping of *ADRB3* polymorphism (rs4994) {#Sec6}
-------------------------------------------

The DNA fragment containing codon 64 of the *ADRB3* gene was amplified by PCR using a sense primer (5′- CCAGTGGGCTGCCAGGGG-3′) and an antisense primer (5′- GCCAGTGGCGCCCAACGG -3′). The PCR conditions were also the same as mentioned above for *ADRB1* studies. Nucleotide sequencing was carried out by the ABI Big Dye Terminator protocol using ABI 3100 Avant Genetic Analyzer.

Statistical analysis {#Sec7}
--------------------

Stat View program for Windows (version 8.0; SAS) was used to conduct all data analyses. Based on the value of BMI, the total population was grouped as normal weight (BMI \< 25 kg/m^2^), overweight (BMI ≥25.1--29.9 kg/m^2^), and obese (≥30 kg/m^2^). The data obtained was analyzed separately for each group and is presented as mean ± SEM. The comparisons of anthropometric parameters and biochemical and hormonal variables between overweight, obese and normal weight control subjects were carried out using the independent student's t-test and ANOVA.

The data were further grouped according to the three genotypes of *ARDB1* and *ARDB3* genes, and the anthropometric measurements, age, BMI, fasting serum insulin, leptin, glucose level and lipid profile, were compared by the Mann-Whitney U- test. To study the influence of the *ARDB1* and *ARDB3* genotypes on BMI, multivariable logistic regression was used. The different parameters were correlated using Pearson's correlation coefficient (r), and the *p*-value was obtained. Frequency distribution analysis was performed using the chi-square test, and frequencies of the different alleles in different groups (normal, overweight and obese) were compared. Relative risk was estimated by the odds ratios (ORs) and their 95% confidence intervals (CIs), and a p-value ≤0.05 was considered statistically significant.

Results {#Sec8}
=======

Obesity-related anthropometric and biochemical characteristics {#Sec9}
--------------------------------------------------------------

Using a BMI cut-off point of BMI \< 25 kg/m^2^, BMI ≥ 25.1--29.9 kg/m^2^) and BMI \> 30 kg/m^2^ for normal weight, overweight and obese, as recommended by the World Health Organization \[[@CR55]\] there were 115, 68, 146 individuals in the normal weight, overweight and obese groups, respectively. The anthropometric characteristics of the study subjects are presented in Table [1](#Tab1){ref-type="table"}. All the three groups matched in their age and no statistically significant differences were observed amongst the groups. All other parameters except HDL, were significantly higher in overweight and obese subjects as compared to the normal weight (control) group (*p* \< 0.0001) as shown in Table [1](#Tab1){ref-type="table"}. The results of biochemical and hormonal parameters are presented in Table [2](#Tab2){ref-type="table"} for the three groups. The value for each parameter was elevated significantly, in the overweight and obese subjects, except HDL, which was significantly lower when compared to the normal weight group (Table [2](#Tab2){ref-type="table"}).Table 1Anthropometric characteristics of control, overweight and obese study subjectsVARIABLESControl\
(*n* = 115) mean ± SEMOverweight\
(*n* = 68) mean ± SEMObese\
(*n* = 146) mean ± SEM*P* valueAge (yr)24.90 ± 0.4425.56 ± 0.5426.70 ± 0.430. 056BMI (kg/m^2^)21.33 ± 0.1926.93 ± 0.1734.89 ± 0.500.0001Waist (cm)70.82 ± 0.7985.13 ± 0.93103.72 ± 1.230.0001Hip (cm)96.13 ± 0.68102.22 ± 0.82119.68 ± 1.150.0001W/H Ratio0.73 ± 0.0060.84 ± 0.0060.87 ± 0.0060.0001Values are mean ± SEM. Abbreviations: BMI, body mass index; W/H, waist/hip ratio; SEM: Standard Error of the MeanTable 2Comparisons of clinical parameters amongst control, overweight and obese study subjectsVARIABLESControl (*n* = 115) mean ± SEMOverweight (*n* = 68) mean ± SEMObese (*n* = 146) mean ± SEM*P* valueCholesterol (mmol/L)3.43 ± 0.044.19 ± 0.094.4 ± 0.070.0001Triglyceride (mmol/L)0.74 ± 0.021.082 ± 0.051.302 ± 0.040.0001HDL (mmol/L)1.32 ± 0.031.19 ± 0.041.07 ± 0.0240.0001LDL -cholesterol (mmol/L)1.55 ± 0.052.07 ± 0.892.56 ± 0.060.0001Leptin (ng/ml)9.42 ± 0.4817.51 ± 0.9736.13 ± 1.670.0001Fasting Insulin (pmol/L)57.21 ± 2.0972.23 ± 4.28106.03 ± 3.070.0001Fasting Glucose (mmol/L)4.71 ± 0.0415.051 ± 0.0575.06 ± 0.050.0001Values are mean ± SEM. *Abbreviations*: Values are mean ± SEM. *Abbreviations*: *HDL*: High-density lipoproteins; *LDL*: Low-density lipoprotein; *SE*: Standard Error of the Mean

Polymorphism in *ADRB1* Arg389Gly genotype {#Sec10}
------------------------------------------

The genotype and allele frequencies of the *ADRB1* Arg389Gly (rs1801253**)** polymorphism were calculated in each group and results were compared. There was no significant difference in the genotype and allelic frequency of *ADRB1* Arg389Gly between control and obese or overweight subjects, as shown in Table [3](#Tab3){ref-type="table"}. The *ADRB1* genotypes (CC, CG, GG) were grouped separately, and the phenotypic characteristics, biochemical and hormonal parameters were calculated separately for each genotype. No significant differences were observed in the results obtained for the three genotypes (Table [4](#Tab4){ref-type="table"}).Table 3Distribution of the genotypes, allele's frequencies and odd ratio of the ADRB1 Arg389Gly polymorphism in control, overweight and obese subjectsGenotypeControl\
T = 115Overweight\
T = 68Obese\
T = 146χ2 Odds ratio (95% CI)*P*- valueGenotype Frequency Arg\\Arg20 (17.4)12 (17.6)18 (12.3)χ2\
Ow = 0.08\
Ob = 0.7\
*-Odds ratio (95% CI) Control* vs *OW 1.09(0.6--1.9)*\
-*Odds ratio (95% CI) Control* vs *Obese 1.2(0.75--1.3)P value for Odds ratio in control* vs *overweight: 0.8 and control* vs *obese:0.4* Arg\\Gly45 (39.1)25 (36.8)57 (39) Gly\\Gly50 (43.5)31 (45.671 (48.6)Allele Frequency Allele Arg38937.0%36%31.8%*Odds ratio (95% CI) Control* vs *OW*\
1.04 (0.67--1.6)\
*Odds ratio (95% CI) Control* vs *Obese1.25(0.9--1.8)P* = 0.86 Allele Gly 38963.o%64%68.2%*P* = 0.22OW = Overweight; Ob = Obese; CI: Confidence interval; χ^2^: Chi squareTable 4Phenotypic characteristics of subjects grouped according to ADRB1 polymorphism at Codon 389Phenotypic variablesArg\\Arg\
(*n* = 50) *mean ± SE*Arg\\Gly\
(*n* = 127) *mean ± SE*Gly\\Gly\
(*n* = 152) *mean ± SEP*-valueBMI (kg/m^2^)28.563±1.16928.500±.6428.489±.59010.998Waist(cm)87.84±2.70688.67±1.64088.31±1.5280.964Hip(cm)107.24±2.343108.33±1.34107.63±1.1950.888W/H ratio.8162±.012.8160±.009.8145±.0080.989Cholesterol (mmol/L)3.936±.12414.016±.07404.043±.07200.749Triglyceride (mmol/L)1.056±0.0680.078±0.04591.048±0.0340.865HDL (mmol/L)1.1986±0.04411.1459±0.02751.2084±0.02990.292LDL (mmol/L)2.072±.1112.094±0.0672.122±0.0680.918Leptin (ng/ml)19.57±2.14923.49±1.6723.60±1.5840.383Fasting Insulin (pmol/L)79.0±5.6884.21±3.3381.09±3.260.677Fasting Glucose(mmol/L)4.900±0.075.002±0.0504.9±0.0430.203Values are mean ± SEM. *Abbreviations*: *BMI*: body mass index; *W/H*: waist hip ratio; High-density lipoproteins; *LDL*: Low-density lipoprotein; *SEM*: Standard Error of the Mean

Polymorphism in ADRB3 Trp64Arg genotype {#Sec11}
---------------------------------------

The frequencies of Trp64Arg (rs4994) alleles and genotypes were calculated. The overweight and obese subjects had a significantly higher genotype and allele frequency of Arg64 compared with normal weight subjects. The genotype and allele frequencies in the total group, are presented in Table [5](#Tab5){ref-type="table"} with the OR, CI, χ^2^ and *p*-value. Furthermore, the study groups were separated according to their Trp64Arg genotypes (TT, TC, CC), and the phenotypic characteristics were obtained. The value of the different parameters in the different genotypes is presented in Table [6](#Tab6){ref-type="table"}. This Table shows that the subjects carrying Arg64 in the homozygous state had a greater BMI, waist and hip circumference, W/H ratio, cholesterol, triglyceride, LDL-C, and plasma leptin, insulin, and glucose compared with those with the Trp64Trp and Trp64Arg genotypes, and the difference was significant. However, the decrease in HDL level was not statistically significant (*p*-value = 0.335) in individuals with different ADRB3 genotypes (Table [6](#Tab6){ref-type="table"}).Table 5The genotypes and allele frequencies of ADRB3 Trp64Arg polymorphism in control, overweight and obese subjects*GenotypeControl*\
*T = 115Overweight*\
*T = 68Obese*\
*T = 146χ* ^*2*^ *Odds ratio (95% CI)P- value*Genotype Frequency Trp\\Trp112 (97.4)61 (89.7)116 (79.5)***χ*** ^*2*^\
*OW = 4.9*\
*Ob = 12.4*\
*Odds ratio (95% CI) Control* vs *OW*\
*4.3 (1--17)*\
*Odds ratio (95% CI) Control* vs *Obese*\
*7 (2--24)P value for Odds ratio in normal* vs *overweight*\
*0.02* *and normal* vs *obese:* *0.0004* Trp\\Arg3 (2.6)7 (10.3)23 (15.8) Arg\\Arg007 (4.8)Allele Frequency Trp6498.7%94.9%87.3%*Odds ratio (95% CI) Control* vs *OW*\
*4.11 (1.04--16.1)*\
*Odds ratio (95% CI) Control* vs *Obese 10.98 (3--36)P* = 0.02 Arg641.3%5.1%12.7%*P* = 0.00001OW = Overweight; Ob = Obese; CI: Confidence interval; ***χ***^***2***^ = Chi squareTable 6Phenotypic Characteristics of subjects grouped according to ADRB3 polymorphism at Codon 64Phenotypic variablesTrp64Trp64\
(*n* = 289)\
*mean ± SE*Trp64Arg64\
(*n* = 33)\
*mean ± SE*Arg64Arg64\
(*n* = 7)\
*mean ± SE*P-valueBMI (kg/m^2^)27.640± 0.40232.48± 6.3645.4± 1.80.0001Waist(cm)86.51± 1.0698.24± 2.95119.14 ± 4.830.0001Hip(cm)106.82± 0.88112.18± 2.55129.57± 3.720.0001W/H ratio0.81 ± 0.010.87 ± 0.020.92 ± 0.040.0001Cholesterol (mmol/L)3.94± 0.054.36± 0.1655.63± 0.320.0001Triglyceride (mmol/L)1.02± 0.031.31± 0.091.643± 0.1810.0001HDL (mmol/L)1.193 ± 0.021.12± 0.051.08± 0.1200.335LDL (mmol/L)2.051± 0.0452.319± 0.1473.286± 0.2440.0001Leptin (ng/ml)21.95± 1.06324.38± 2.5257.14± 10.740.0001Fasting Insulin (pmol/L)79.018± 2.24101.6± 6.88111.70± 17.370.001Fasting Glucose(mmol/L)4.903± 0.0305.234± 0.124.89± 0.060.003Values are mean ± SEM. *Abbreviations*: *BMI*, body mass index; *W/H*, waist hip ratio

Discussion {#Sec12}
==========

This is the first study to report the relationship between *ADRB1* and *ADRB3* gene polymorphism and obesity-related phenotypes in the Saudi population. Since in our previous report, we had observed an association between Gln27Glu polymorphism of *ADRB2* gene, obesity, and other related disorders in Saudi population \[[@CR9]\] our interest was to explore if any association existed between *ADRB1* (rs1801253**)** and *ADRB3* (rs4994) and these abnormalities. Hence, during this study, a large cohort of 329 subjects was genotyped for Gly389Arg in *ADRB1* (rs1801253**)** and Trp64Arg in *ADRB3* (rs4994) genes and the association of the variant allele with metabolic parameters were analyzed. The results of our investigation have clearly highlighted the strong association with *ADRB3* polymorphism, where the mutant Arg allele in *ADRB3*, significantly associates with a greater body weight and higher BMI, elevated leptin and dyslipidaemias both in heterozygous and homozygous. It also results in elevated blood glucose level and hyperinsulinaemia. However, the *ADRB1* polymorphism Arg389Gly, shows no association either with the BMI or related disorders. The *ADRB1* is a candidate gene for obesity due to its role in catecholamine mediated energy homeostasis. In 2008, Ohshiro and coworkers had shown a strong association between mutations in the *ADRB1* and massive obesity in Japanese \[[@CR56]\]. In obese individuals, the degree of weight loss during a very low calorie diet has been shown to correlate with changes in ADRB1 protein concentration in adipose tissue \[[@CR57], [@CR58]\]. An investigation involving a population cohort of 761 women indicated that women carrying the Gly49 genotype had greater elevation in BMI over 15 years compared to those with the Ser49 genotype \[[@CR59]\]. Dionne et al., \[[@CR7]\] reported that Gly389Arg exhibited a strong relationship with obesity in Caucasian women. In contrast, some studies have reported the Arg389Gly polymorphism had no significant relationship to obesity in Danish \[[@CR21]\], Swedish \[[@CR60]\] and Japanese \[[@CR56]\] subjects, suggesting that it has no role in human obesity. Masuo and Lambert \[[@CR10]\] have reviewed various studies about the relationship of polymorphism in either Gly49-Gly389 or Ser49Gly- Arg389Gly in *ADRB1* with obesity or obesity related disorders and have reported contradicting findings among different populations which means that the relationship of *ADRB1* polymorphism to obesity could vary between different populations. In fact, our findings for Arg389 Gly polymorphism in *ADRB1* amongst Saudi population are in line with earlier published reports \[[@CR7], [@CR21], [@CR61], [@CR62]\] and suggest that *ADRB1* Arg389Gly polymorphisms do not contribute to obesity and related disorders in the Saudi population.

The *ADRB3* gene is expressed in adipose tissues and stimulates the mobilization of lipids from the WAT and increases thermo-genesis in BAT \[[@CR10]\]. Mutation of *ADRB3* in WAT could slow lipolysis and thereby cause the retention of lipids in adipocytes and may contribute to visceral obesity in humans. Interestingly, extensive studies have investigated the role of Trp64Arg (rs4994) in the development of obesity, T2DM, hypertension (HT), cardiovascular disease CAD, dyslipidaemias. Table [7](#Tab7){ref-type="table"} summarizes some of the studies reported from different populations and shows that there are extensive contradictions between populations, between genders and within different female age groups. Some studies suggest a strong relationship between obesity and Trp64Arg polymorphism in some populations \[[@CR20], [@CR26]--[@CR28], [@CR31]--[@CR33], [@CR35], [@CR37]--[@CR40], [@CR45], [@CR48], [@CR51], [@CR61]--[@CR65]\]. Whereas, other studies on same or different populations have failed to show any association \[[@CR21], [@CR36], [@CR41], [@CR46], [@CR49], [@CR50], [@CR52]\]. Even within the same population there are contradictory reports (Table [7](#Tab7){ref-type="table"}). This makes the study of Trp64Arg polymorphism necessary in every population. The present study has found a strong relationship between obesity and Trp64Arg polymorphism in the Saudi population. This is a similar association that we have shown earlier to exist between Gln27Glu polymorphism in *ADRB2* gene and obesity related disorders such as hypertriglyceridemia, hyperinsulinemia, and hyperleptinemia in Saudis \[[@CR9]\].Table 7Studies reporting the association of Trp64Arg (rs4994) with obesity and obesity-related disorders in different populationsPopulationStudy showed rs4994:ReferencesAsiansAssociation with T2DM (meta-analysis)\[26\]Non-AsiansNo associationAsiansAssociation with BMI (meta-analysis)40African AmericanNo association with BMI52S. African womenNo association with MS41Brazilians/CaucasiansCombined effect in the modulation of OW/obesity and HDL-C in T2DM31BalineseAssociation with obesity in rural females only38CaucasiansAssociation with elevated BMI and BMD48Chile (Ayara natives)No association with BMI50ChineseAssociation with HT and dyslipidaemias (metaanalysis)27Hungarian childrenAssociation with increase body weight and BMI28S. ItaliansInsulin resistance in males only46JapaneseAssociation with increase BMI51No association with BMI49No relation with MS45Japanese childrenAssociation with increases visceral fat, blood pressure, triglycerides and reduced TAG32Japanese menAssociation with annual weight gain35KashmirisAssociation with increase BMI, W/H ratio, dyslipidaemias, uncontrolled T2DM53KyrgyAssociation with increase obesity, abdominal obesity, decreased HDL37MexicanAssociation with increase T2DM and MS39, 29RussiansAssociation with increase fat, glucose level, and uric acid33S. SpainAssociation with T2DM44TaiwaneseNo association with obesity36SaudisObesity, hyperlipidaemias, hyperinsulinaemia, hyperleptinaemia.This study

The *ADRB2* and *ARDB3* gene polymorphisms may act as predictive markers for obesity and obesity related disorders in Saudis.

Conclusion {#Sec13}
==========

Our present results shows for the first time that obesity and related disorders in Saudis are linked to polymorphism of Trp64Arg (rs4994) in *ADRB3* gene but not to Arg389Gly (rs1801253) in *ARDB1* gene.
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